{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:47:07Z","timestamp":1792860427416,"version":"4.5.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.atherosclerosis.2017.10.025","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T02:30:51Z","timestamp":1508466651000},"page":"49-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":213,"special_numbering":"C","title":["Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism"],"prefix":"10.1016","volume":"267","author":[{"given":"Anna","family":"Wolska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6668-1916","authenticated-orcid":false,"given":"Lita A.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4429-8924","authenticated-orcid":false,"given":"Masako","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo J.","family":"Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis O.","family":"Sviridov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/VHRM.S104369","article-title":"Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease","volume":"12","author":"Toth","year":"2016","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.atherosclerosis.2013.12.047","article-title":"New and emerging regulators of intestinal lipoprotein secretion","volume":"233","author":"Xiao","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9258(18)66011-9","article-title":"Clearing factor, a heparin-activated lipoprotein lipase. I. Isolation and characterization of the enzyme from normal rat heart","volume":"215","author":"Korn","year":"1955","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib7","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1016\/S0021-9258(18)62574-8","article-title":"Further characterization of apolipoproteins from the human plasma very low density lipoproteins","volume":"245","author":"Brown","year":"1970","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0006-291X(70)90468-7","article-title":"A\u00a0specific apoprotein activator for lipoprotein lipase","volume":"41","author":"LaRosa","year":"1970","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM197806082982301","article-title":"Hypertriglyceridemia associated with deficiency of apolipoprotein C-II","volume":"298","author":"Breckenridge","year":"1978","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib11","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome, Arteriosclerosis","volume":"28","author":"Adiels","year":"2008","journal-title":"Thrombosis, Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/ATVBAHA.111.241471","article-title":"Intracellular trafficking and secretion of VLDL, Arteriosclerosis","volume":"32","author":"Tiwari","year":"2012","journal-title":"Thrombosis, Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib13","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1210\/jc.2005-1709","article-title":"Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states","volume":"91","author":"Barrows","year":"2006","journal-title":"J.\u00a0Clin. Endocrinol. Metabolism"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib14","article-title":"Lipoprotein lipase: physiology, biochemistry, and molecular biology, Frontiers in bioscience","volume":"6","author":"Goldberg","year":"2001","journal-title":"a J. virtual Libr."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00109-002-0384-9","article-title":"Lipoprotein lipase: structure, function, regulation, and role in disease","volume":"80","author":"Mead","year":"2002","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib16","doi-asserted-by":"crossref","first-page":"33623","DOI":"10.1074\/jbc.M109.049395","article-title":"Lipase maturation factor LMF1, membrane topology and interaction with lipase proteins in the endoplasmic reticulum","volume":"284","author":"Doolittle","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib17","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1194\/jlr.M011155","article-title":"Lipase maturation factor 1 is required for endothelial lipase activity","volume":"52","author":"Ben-Zeev","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cmet.2014.06.015","article-title":"The ER-associated degradation adaptor protein Sel1L regulates LPL secretion and lipid metabolism","volume":"20","author":"Sha","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1042\/bj2870337","article-title":"Regulation of the synthesis, processing and translocation of lipoprotein lipase","volume":"287","author":"Braun","year":"1992","journal-title":"Biochem. J."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1194\/jlr.M072520","article-title":"Mobility of \u201cHSPG-bound\u201d LPL explains how LPL is able to reach GPIHBP1 on capillaries","volume":"58","author":"Allan","year":"2017","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cmet.2007.02.002","article-title":"Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons","volume":"5","author":"Beigneux","year":"2007","journal-title":"Cell Metab."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cmet.2010.04.016","article-title":"GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries","volume":"12","author":"Davies","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cmet.2014.01.017","article-title":"The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries","volume":"19","author":"Goulbourne","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib24","article-title":"The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain","volume":"5","author":"Mysling","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbalip.2014.03.013","article-title":"Physiological regulation of lipoprotein lipase","volume":"1841","author":"Kersten","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib26","doi-asserted-by":"crossref","first-page":"25383","DOI":"10.1074\/jbc.M501589200","article-title":"Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism","volume":"280","author":"Lookene","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib27","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1172\/JCI67398","article-title":"Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans","volume":"123","author":"Gonzales","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib28","doi-asserted-by":"crossref","first-page":"29554","DOI":"10.1074\/jbc.M802579200","article-title":"The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons","volume":"283","author":"Gin","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0009-8981(75)90374-5","article-title":"Effects of apolipoproteins on lipoprotein lipase activity of human adipose tissue","volume":"63","author":"Ekman","year":"1975","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0006-291X(72)80149-9","article-title":"Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein","volume":"46","author":"Brown","year":"1972","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1194\/jlr.M400301-JLR200","article-title":"Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL","volume":"46","author":"Berbee","year":"2005","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib32","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/S0022-2275(20)32211-2","article-title":"Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice","volume":"42","author":"Jong","year":"2001","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib33","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib34","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/eci.12657","article-title":"Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III","volume":"46","author":"Ooi","year":"2016","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib35","doi-asserted-by":"crossref","first-page":"18259","DOI":"10.1016\/S0021-9258(18)55263-7","article-title":"Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway","volume":"266","author":"Sehayek","year":"1991","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tcm.2007.10.003","article-title":"The role of angiopoietin-like proteins in angiogenesis and metabolism","volume":"18","author":"Hato","year":"2008","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib37","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbalip.2011.10.010","article-title":"Regulation of triglyceride metabolism by Angiopoietin-like proteins","volume":"1821","author":"Mattijssen","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.biochi.2013.08.011","article-title":"From fatty-acid sensing to chylomicron synthesis: role of intestinal lipid-binding proteins","volume":"96","author":"Buttet","year":"2014","journal-title":"Biochimie"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib39","doi-asserted-by":"crossref","first-page":"8342","DOI":"10.1073\/pnas.88.19.8342","article-title":"Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein","volume":"88","author":"Beisiegel","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib40","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJM197811302992207","article-title":"Plasma high-density lipoproteins","volume":"299","author":"Tall","year":"1978","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib41","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/bi00337a028","article-title":"Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages","volume":"24","author":"Zannis","year":"1985","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib42","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1016\/S0021-9258(18)50321-5","article-title":"Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat","volume":"254","author":"Wu","year":"1979","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1677\/JOE-08-0238","article-title":"Apolipoprotein A-I, A-II, C-II, and H expression in the developing lung and sex difference in surfactant lipids","volume":"200","author":"Provost","year":"2009","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib44","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.earlhumdev.2010.06.013","article-title":"Elevated expression of four apolipoprotein genes during the 32-35 week gestation window in the human developing lung","volume":"86","author":"Provost","year":"2010","journal-title":"Early Hum. Dev."},{"issue":"111","key":"10.1016\/j.atherosclerosis.2017.10.025_bib45","article-title":"Apolipoprotein C-II and lipoprotein lipase show a temporal and geographic correlation with surfactant lipid synthesis in preparation for birth","volume":"10","author":"Cote","year":"2010","journal-title":"BMC Dev. Biol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib46","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1167\/iovs.05-1446","article-title":"Apolipoprotein localization in isolated drusen and retinal apolipoprotein gene expression","volume":"47","author":"Li","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2017.07.010","article-title":"The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease","author":"Fessler","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2015.06.042","article-title":"Liver X receptors at the intersection of lipid metabolism and atherogenesis","volume":"242","author":"Lee","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib49","doi-asserted-by":"crossref","first-page":"13925","DOI":"10.1074\/jbc.R116.774745","article-title":"Current prospects of type II interferon gamma signaling and autoimmunity","volume":"292","author":"Green","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145626","article-title":"Deregulated lipid sensing by intestinal CD36 in diet-induced hyperinsulinemic obese mouse model","volume":"11","author":"Buttet","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib51","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0022-2275(20)35732-1","article-title":"Localization of a liver-specific enhancer in the apolipoprotein E\/C-I\/C-II gene locus","volume":"34","author":"Shachter","year":"1993","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib52","doi-asserted-by":"crossref","first-page":"29113","DOI":"10.1074\/jbc.272.46.29113","article-title":"Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E\/C-I\/C-IV\/C-II gene cluster","volume":"272","author":"Allan","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib53","doi-asserted-by":"crossref","first-page":"26278","DOI":"10.1074\/jbc.270.44.26278","article-title":"Evolutionary duplication of a hepatic control region in the human apolipoprotein E gene locus. Identification of a second region that confers high level and liver-specific expression of the human apolipoprotein E gene in transgenic mice","volume":"270","author":"Allan","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib54","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1210\/mend.15.10.0712","article-title":"Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids","volume":"15","author":"Kast","year":"2001","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib55","doi-asserted-by":"crossref","first-page":"31900","DOI":"10.1074\/jbc.M202993200","article-title":"Regulated expression of the apolipoprotein E\/C-I\/C-IV\/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta","volume":"277","author":"Mak","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1042\/bj20021532","article-title":"Synergism between nuclear receptors bound to specific hormone response elements of the hepatic control region-1 and the proximal apolipoprotein C-II promoter mediate apolipoprotein C-II gene regulation by bile acids and retinoids","volume":"372","author":"Kardassis","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib57","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/MCB.21.4.1393-1403.2001","article-title":"Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis","volume":"21","author":"Hayhurst","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib58","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cca.2015.10.033","article-title":"Update on the molecular biology of dyslipidemias","volume":"454","author":"Ramasamy","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib59","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1074\/jbc.273.7.4188","volume":"273","author":"Vorgia","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib60","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0022-2275(20)37463-0","article-title":"A\u00a0single nucleotide substitution in the promoter region of the apolipoprotein C-II gene identified in individuals with chylomicronemia","volume":"37","author":"Streicher","year":"1996","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib61","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1074\/jbc.273.28.17810","article-title":"Transactivation of the human apolipoprotein CII promoter by orphan and ligand-dependent nuclear receptors. The regulatory element CIIC is a thyroid hormone response element","volume":"273","author":"Kardassis","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib62","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cmet.2015.02.004","article-title":"A\u00a0liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice","volume":"21","author":"Li","year":"2015","journal-title":"Cell Metab."},{"issue":"Suppl 3","key":"10.1016\/j.atherosclerosis.2017.10.025_bib63","first-page":"49","article-title":"Structure of the human apolipoprotein C-II gene promoter","volume":"34","author":"Streicher","year":"1996","journal-title":"Z\u00a0Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MOL.0b013e3283508fed","article-title":"The role of CREB-H transcription factor in triglyceride metabolism","volume":"23","author":"Lee","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib65","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/01.ATV.19.1.115","article-title":"Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation","volume":"19","author":"Andersson","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"27","key":"10.1016\/j.atherosclerosis.2017.10.025_bib66","article-title":"The effect of maternal undernutrition on the rat placental transcriptome: protein restriction up-regulates cholesterol transport","volume":"11","author":"Daniel","year":"2016","journal-title":"Genes Nutr."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib67","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.metabol.2011.12.002","article-title":"A\u00a0review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease","volume":"61","author":"Kei","year":"2012","journal-title":"Metabolism Clin. Exp."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib68","doi-asserted-by":"crossref","first-page":"14683","DOI":"10.1074\/jbc.M512636200","article-title":"Partnership of PGC-1alpha and HNF4alpha in the regulation of lipoprotein metabolism","volume":"281","author":"Rhee","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib69","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1194\/jlr.M035568","article-title":"Macrophage lipoprotein lipase modulates the development of atherosclerosis but not adiposity","volume":"54","author":"Takahashi","year":"2013","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib70","doi-asserted-by":"crossref","first-page":"13891","DOI":"10.1074\/jbc.M110.179572","article-title":"Macrophage-specific up-regulation of apolipoprotein E gene expression by STAT1 is achieved via long range genomic interactions","volume":"286","author":"Trusca","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib71","doi-asserted-by":"crossref","first-page":"17527","DOI":"10.1074\/jbc.M910376199","article-title":"Combined serum paraoxonase knockout\/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis","volume":"275","author":"Shih","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib72","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1523\/JNEUROSCI.21-03-00812.2001","article-title":"Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain","volume":"21","author":"Grehan","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib73","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1006\/bbrc.2000.4219","article-title":"Apolipoprotein specificity for lipid efflux by the human ABCAI transporter","volume":"280","author":"Remaley","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib74","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/jcb.22713","article-title":"Tgif1 represses apolipoprotein gene expression in liver","volume":"111","author":"Melhuish","year":"2010","journal-title":"J.\u00a0Cell Biochem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib75","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1189\/jlb.69.4.645","article-title":"Expression of the apolipoprotein C-II gene during myelomonocytic differentiation of human leukemic cells","volume":"69","author":"Chun","year":"2001","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040463","article-title":"STAT1 interacts with RXRalpha to upregulate ApoCII gene expression in macrophages","volume":"7","author":"Trusca","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib77","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/S0021-9258(17)40852-0","article-title":"Identification of circulating apolipoproteins synthesized by rat small intestine in\u00a0vivo","volume":"253","author":"Wu","year":"1978","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib78","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0022-2275(20)38495-9","article-title":"Apolipoprotein C-II deficiency: detection of immunoreactive apolipoprotein C-II in the intestinal mucosa of two patients","volume":"29","author":"Capurso","year":"1988","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib79","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0026-0495(76)90084-6","article-title":"Alterations in levels and interrelations of plasma apolipoproteins induced by diet","volume":"25","author":"Schonfeld","year":"1976","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib80","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1385\/CP:2:1:103","article-title":"Mass determination of major plasma proteins by matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry","volume":"2","author":"Hortin","year":"2006","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib81","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/jpet.115.229740","article-title":"Creation of apolipoprotein C-II (ApoC-II) mutant mice and correction of their hypertriglyceridemia with an ApoC-II mimetic peptide","volume":"356","author":"Sakurai","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib82","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1373\/clinchem.2008.108175","article-title":"High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance","volume":"54","author":"Hortin","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib83","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0009-8981(01)00591-5","article-title":"Reference intervals for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking, and Lp(a) level","volume":"312","author":"Sakurabayashi","year":"2001","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib84","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1464-5491.2009.02757.x","article-title":"Parallel increase of plasma apoproteins C-II and C-III in Type 2 diabetic patients","volume":"26","author":"Beliard","year":"2009","journal-title":"Diabet. Med."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib85","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000185138","article-title":"Lipoproteins and apolipoproteins during the progression of chronic renal disease","volume":"50","author":"Grutzmacher","year":"1988","journal-title":"Nephron"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib86","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1021\/bi002821m","article-title":"NMR structure of human apolipoprotein C-II in the presence of sodium dodecyl sulfate","volume":"40","author":"MacRaild","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib87","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1021\/bi0267184","article-title":"Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase","volume":"42","author":"Zdunek","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib88","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-2275(20)41536-6","article-title":"The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function","volume":"33","author":"Segrest","year":"1992","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib89","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0005-2760(79)90224-8","article-title":"Activation of lipoprotein lipase by native and acylated peptides of apolipoprotein C-II","volume":"573","author":"Musliner","year":"1979","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib90","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2013current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib91","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11010-008-0005-1","article-title":"Hypertriglyceridemia: phenomics and genomics","volume":"326","author":"Hegele","year":"2009","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib92","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1074\/jbc.M109.022046","article-title":"Site-directed mutagenesis of apolipoprotein CII to probe the role of its secondary structure for activation of lipoprotein lipase","volume":"285","author":"Shen","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib93","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.114.220418","article-title":"A\u00a0novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice","volume":"352","author":"Amar","year":"2015","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib94","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1074\/jbc.M105421200","article-title":"Functional analyses of human apolipoprotein CII by site-directed mutagenesis: identification of residues important for activation of lipoprotein lipase","volume":"277","author":"Shen","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib95","doi-asserted-by":"crossref","first-page":"23027","DOI":"10.1074\/jbc.M300315200","article-title":"Identification of a lipoprotein lipase cofactor-binding site by chemical cross-linking and transfer of apolipoprotein C-II-responsive lipolysis from lipoprotein lipase to hepatic lipase","volume":"278","author":"McIlhargey","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib96","doi-asserted-by":"crossref","first-page":"25396","DOI":"10.1074\/jbc.270.43.25396","article-title":"Human hepatic and lipoprotein lipase: the loop covering the catalytic site mediates lipase substrate specificity","volume":"270","author":"Dugi","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib97","doi-asserted-by":"crossref","first-page":"30979","DOI":"10.1074\/jbc.273.47.30979","article-title":"Subdomain chimeras of hepatic lipase and lipoprotein lipase. Localization of heparin and cofactor binding","volume":"273","author":"Hill","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib98","doi-asserted-by":"crossref","first-page":"18029","DOI":"10.1074\/jbc.M114.629865","article-title":"A\u00a0pressure-dependent model for the regulation of lipoprotein lipase by apolipoprotein C-II","volume":"290","author":"Meyers","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","article-title":"Diagnostic algorithm for familial chylomicronemia syndrome","volume":"23","author":"Stroes","year":"2017","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/CIRCGENETICS.111.960864","article-title":"Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia","volume":"5","author":"Johansen","year":"2012","journal-title":"Circ. Cardiovasc Genet."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib101","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00002018-200124060-00003","article-title":"Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels","volume":"24","author":"Mantel-Teeuwisse","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib102","unstructured":"Herink M, IM, Medication induced changes in lipid and lipoproteins, In: De Groot LJ, C.G, Dungan K, et\u00a0al (ed), Endotext (Internet), MDText.com, Inc., South Dartmouth (MA), Updated 2015 Jul 27, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326739\/."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib103","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ymgme.2007.10.007","article-title":"Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum","volume":"93","author":"Rahalkar","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib104","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease, Online","article-title":"Familial lipoprotein lipase deficiency, apo C-II deficiency, and hepatic lipase deficiency","author":"Brunzell JD","year":"2016"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib105","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1002\/art.10624","article-title":"Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus","volume":"46","author":"Reichlin","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib106","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1210\/jc.2013-3619","article-title":"Autoimmune severe hypertriglyceridemia induced by anti-apolipoprotein C-II antibody","volume":"99","author":"Yamamoto","year":"2014","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib107","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4300\/JGME-D-16-00503.1","article-title":"Residents' exposure to educational experiences in facilitating hospital discharges","volume":"9","author":"Young","year":"2017","journal-title":"J.\u00a0Grad. Med. Educ."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib108","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/ncpendmet0982","article-title":"A\u00a0diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias","volume":"4","author":"de Graaf","year":"2008","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib109","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-4684-5904-3_40","article-title":"Molecular genetics of apoC-II and lipoprotein lipase deficiency","volume":"285","author":"Fojo","year":"1991","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096482","article-title":"Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects","volume":"9","author":"Di Filippo","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2017.10.025_bib111","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1210\/jc.2016-3903","article-title":"A\u00a0novel APOC2 missense mutation causing apolipoprotein C-II deficiency with severe triglyceridemia and pancreatitis","volume":"102","author":"Ueda","year":"2017","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib112","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/0026-0495(78)90288-3","article-title":"Lipoprotein lipase activity in adipose tissue and skeletal muscle of runners: relation to serum lipoproteins","volume":"27","author":"Nikkil\u00e4","year":"1978","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib113","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1194\/jlr.D045963","article-title":"LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias","volume":"55","author":"Johansen","year":"2014","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib114","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1073\/pnas.74.11.4848","article-title":"Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II","volume":"74","author":"Kinnunen","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.10702","article-title":"Diagnosis and management of type I and type V hyperlipoproteinemia","volume":"19","author":"Gotoda","year":"2012","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib116","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.08.002","article-title":"National lipid association annual summary of clinical lipidology","volume":"10","author":"Bays","year":"2016","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib117","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib118","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1194\/jlr.M200282-JLR200","article-title":"Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance","volume":"44","author":"Park","year":"2003","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib119","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/ajcn\/53.5.1185","article-title":"Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans","volume":"53","author":"Nord\u00f8y","year":"1991","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib120","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib121","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.10.025_bib122","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.10.025_bib123","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib124","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1194\/jlr.M074880","article-title":"Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E","volume":"58","author":"Millar","year":"2017","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2017.10.025_bib125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2042018817695449","article-title":"Therapeutic plasmapheresis for hypertriglyceridemia-associated acute pancreatitis: case series and review of the literature","volume":"8","author":"Joglekar","year":"2017","journal-title":"Ther. Adv. Endocrinol. metabolism"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501731345X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501731345X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T06:30:56Z","timestamp":1693117856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191501731345X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":125,"alternative-id":["S002191501731345X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.10.025","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}